

T
x

Related Searches:



Private Equity Investments

---

Credit Crisis 2008

Chinese Investors

Current Inflation Rate

Money Supply

Private Equity Deals

Credit Crisis

Average Annual Inflation Rate

Published on [Business Spectator](http://www.businessspectator.com.au) (<http://www.businessspectator.com.au>)

## Benitec Biopharma to raise up to \$31.5 mn

[Australian](#) gene [technology company](#) Benitec Biopharma is tapping US institutional investors for up to \$31.5 million in a [private placement](#), in an attempt to capitalise on recent share price wins in the US biotech sector.

Specialist institutional [healthcare](#) investor RA [Capital Management](#) will take the largest block of shares. Fellow US biotech and healthcare institutional investors Perceptive Advisors, [Special Situations Fund](#) and Sabby Management also threw their hats in the ring.

The funds will be used for a [Hepatitis C](#) trial and the development of [lung cancer](#), age-[related macular degeneration](#) and Hepatitis B programs. The group's value lies in its patent of the ddRNAi "gene-silencing" technology, which is intended to inactivate disease-inducing genes.

The [placement](#) is for up to 29.4 million fully-paid [ordinary shares](#) at \$1.07 each. Investors will get free attaching options, with a five-year expiry date, to purchase up to an additional 13.2 million ordinary shares at an exercise price of \$1.26.

A rise in the [share price](#) of similar US-based "gene-silencing" companies like Alnylam, Arrowhead and Dicerna this month had prompted Benitec to tap the market, company [chief executive](#) Peter French said.

"The [appetite](#) for biotechnology investment is very strong at the moment, particularly in the US," Dr French said. He said growing interest from institutional US investors had prompted the steep rise in Benitec's share price in the past fortnight.

Shares closed 16.35 per cent higher at \$1.85 today. The stock's value has more than doubled this month.

The placement was managed by US [investment bank](#) **Maxim Group** and Lodge [Corporate](#) in Australia.

(Reporting by [Amanda.saunders@businessspectator.com.au](mailto:Amanda.saunders@businessspectator.com.au) [1])

Editing by [Miranda.Maxwell@businessspectator.com.au](mailto:Miranda.Maxwell@businessspectator.com.au) [2] )

Author

[Amanda Saunders](#) [3]

Quick Summary

The funds will be used for a Hepatitis C trial and the development of programs for lung cancer, age-related [macular degeneration](#) and Hepatitis B.

Associated image

Media

Categories

[DataRoom](#) [4]

[Equity Capital Markets](#) [5]

[Industries](#) [6]

[Health and Pharmaceuticals](#) [7]

Primary category

[Industries](#) [6]

[Health and Pharmaceuticals](#) [7]

Status

Published

Content Channel

[Business Spectator](#) [8]

---

### Source URL:

<http://www.businessspectator.com.au/news/2014/2/24/health-and-pharmaceuticals/benitec-biopharma-raise-315-mn>

### Links

[1] <mailto:Amanda.saunders@businessspectator.com.au>

[2] <mailto:Victoria.Thieberger@businessspectator.com.au>

[3] <http://www.businessspectator.com.au/contributor/amanda-saunders>

[4] <http://www.businessspectator.com.au/dataroom>

[5] <http://www.businessspectator.com.au/dataroom/equity-capital-markets>

[6] <http://www.businessspectator.com.au/industries>

[7] <http://www.businessspectator.com.au/industries/health-and-pharmaceuticals>

[8] <http://www.businessspectator.com.au/content-channel/business-spectator>